| Zusammenfassung: | <h4>Aims</h4> <p>Renin-angiotensin system blockers reduce the incidence and progression of microalbuminuria and the subsequent development of end-stage renal disease (ESRD) in patients with type 2 diabetes. We aimed to examine the effect of valsartan on kidney outcomes in patients with impaired glucose tolerance (IGT).</p> <h4>Methods</h4> <p>In a double-blind randomized trial, 9306 patients with IGT were assigned to valsartan (160 mg daily) or placebo. The co-primary endpoints were the development of diabetes and two composite cardiovascular outcomes. Prespecified renal endpoints included the composite of renal death, ESRD, or doubling of serum creatinine; estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m2; hospitalization for renal failure; and progression from normoalbuminuria to microalbuminuria, microalbuminuria to macroalbuminuria, and normoalbuminuria to macroalbuminuria. The median follow-up was 6.2 years.</p> <h4>Results</h4> <p>Valsartan reduced the incidence of diabetes but not cardiovascular events. In the valsartan group, 25/4631 patients (0.5%), versus 26/4675 (0.6%) patients in the placebo group, developed ESRD or experienced doubling of serum creatinine (HR 0.96, 95% CI 0.55–1.66, P=0.87). Few patients in either group developed an eGFR of ≤30 mL/min/1.73m2 or had a renal hospitalization. Fewer patients on valsartan (237/4084 [5.8%]) than on placebo (342/4092 [8.4%]) developed microalbuminuria (HR 0.68, 95% CI 0.57–0.80; P<0.0001), and fewer valsartan-treated patients developed macroalbuminuria. Overall, UACR was 11% lower with valsartan (95% CI 8–13%, P<0.0001); 9% (95% CI 6–11%, P<0.0001) lower after adjusting for both glucose and blood pressure.</p> <h4>Conclusion</h4> <p>The effect of valsartan on urinary albumin-to-creatinine ratio was not wholly explained by change in blood pressure or glucose. Valsartan reduced the incidence of microalbuminuria in IGT without increasing the incidence of hyperkalemia or renal dysfunction compared with placebo.</p>
|
|---|